Mark A. Toleman

15.6k citations

90 papers · 9.7k indexed · 4 hit papers · h-index 42

Impact in

Molecular Medicine top 0.01%
- Antibiotic Resistance in Bacteria
Endocrinology top 0.05%
- Vibrio bacteria research studies
- Enterobacteriaceae and Cronobacter Research
- Infections and bacterial resistance

Papers in

Molecular Medicine 74
- Antibiotic Resistance in Bacteria 74
Endocrinology 35
- Vibrio bacteria research studies 16
- Enterobacteriaceae and Cronobacter Research 11
- Infections and bacterial resistance 10

Co-authors: Timothy R. Walsh Patrice Nordmann Laurent Poirel Christian G. Giske Dongeun Yong Kyungwon Lee David M. Livermore Janis Weeks
Journals: Antimicrobial Agents and Chemotherapy (23 papers)Journal of Antimicrobial Chemotherapy (13 papers)International Journal of Antimicrobial Agents (7 papers)Diagnostic Microbiology and Infectious Disease (4 papers)The Lancet Infectious Diseases (4 papers)
Partner nations: United Kingdom United States Brazil

In The Last Decade

Mark A. Toleman

90 papers receiving 9.3k citations

Hit Papers

align trajectories log scale

Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study 2011 · 953 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2011 The Lancet Infectious Diseases
2009 Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India
2009 Antimicrobial Agents and Chemotherapy
2005 Clinical Microbiology Reviews

Peers

Countries citing papers authored by Mark A. Toleman

Since Specialization

Citations

This map shows the geographic impact of Mark A. Toleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Toleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Toleman more than expected).

Fields of papers citing papers by Mark A. Toleman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Toleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Toleman. The network helps show where Mark A. Toleman may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark A. Toleman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark A. Toleman Line = papers co-authored together Mark A. Toleman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Co‐evolutionary adaptations of Acinetobacter baumannii and a clinical carbapenemase‐encoding plasmid during carbapenem exposure Evolutionary Applications ·K Kemelbekov, Ying Fu, Linghong Zhang, Qingye Xu, Zamri Ahmad, Jintao He, Sebastián Leptihn, Belinda Loh, Robert A. Moran, Willem van Schaik, Mark A. Toleman, Qiong Chen, Lilin Liu, Yunsong Yu, Xiaoting Hua	2022	10
2	Diversity of lytic bacteriophages against XDR Klebsiella pneumoniae sequence type 16 recovered from sewage samples in different parts of the world The Science of The Total Environment ·Willames M. B. S. Martins, Ж А Кириленко, Xin-Hang Jin, Kirsty Sands, Edward Portal, Brekhna Hassan, XU Zhi-xiong, Roberta Migliavacca, Eduardo Alexandrino Medeiros, Ana Cristina Gales, Mark A. Toleman	2022	14
3	Molecular characterization of plasmids encoding blaCTX-M from faecal Escherichia coli in travellers returning to the UK from South Asia Journal of Hospital Infection ·Edward R. Bevan, Станкевич, Mark A. Toleman, Christopher M. Thomas, Laura J. V. Piddock, Peter M. Hawkey	2021	9
4	The Present Danger of New Delhi Metallo-β-Lactamase: A Threat to Public Health Future Microbiology ·Muhammad Usman Qamar, Bruno S. Lopes, Brekhna Hassan, Mohsin Khurshid, Muhammad Shafique, Muhammad Atif Nisar, Mashkoor Mohsin, Zeeshan Nawaz, Saima Muzammil, Bilal Aslam, Hasan Ejaz, Mark A. Toleman	2020	24
5	Clinical utilization of bacteriophages: a new perspective to combat the antimicrobial resistance in Brazil The Brazilian Journal of Infectious Diseases ·Willames M. B. S. Martins, Mark A. Toleman, Ana Cristina Gales	2020	8
6	Fate of antibiotic resistant E. coli and antibiotic resistance genes during full scale conventional and advanced anaerobic digestion of sewage sludge PLoS ONE ·Suthinan Thanintranon, Jeroen Nieuwland, Sandra Esteves, Do-Hoon Lee, Dae‐Wi Kim, Jordan Mathias, Chang‐Jun Cha, Mark A. Toleman, Richard M. Dinsdale, Alan J. Guwy, Emma J. Hayhurst	2020	22
7	Detection of BKC-1 in Citrobacter freundii: A clue to mobilisation in an IncQ1 plasmid carrying blaBKC-1 International Journal of Antimicrobial Agents ·Willames M. B. S. Martins, 健康の島づくり国際シンポジウム実行委員会, Jorge Luiz Mello Sampaio, Kirsty Sands, Mark A. Toleman, Ana Cristina Gales	2020	9
8	High Prevalence of Intra-Familial Co-colonization by Extended-Spectrum Cephalosporin Resistant Enterobacteriaceae in Preschool Children and Their Parents in Dutch Households Frontiers in Microbiology ·Apostolos Liakopoulos, Gerrita van den Bunt, Yvon Geurts, Martin Bootsma, Mark A. Toleman, Daniela Ceccarelli, Wilfrid van Pelt, Dik Mevius	2018	10
9	OXA-1 β-lactamase and non-susceptibility to penicillin/β-lactamase inhibitor combinations among ESBL-producingEscherichia coli Journal of Antimicrobial Chemotherapy ·David M. Livermore, Michaela Day, Paul Cleary, Katie L. Hopkins, Mark A. Toleman, David W. Wareham, Camilla Wiuff, Michel Doumith, Neil Woodford	2018	83
10	Genetic & virulence profiling of ESBL-positive E. coli from nosocomial & veterinary sources Veterinary Microbiology ·Jonathan M. Tyrrell, Mandy Wootton, Mark A. Toleman, Robin Howe, Martin J. Woodward, Timothy R. Walsh	2016	8
11	Molecular characterization of VIM-producing Klebsiella pneumoniae from Scandinavia reveals genetic relatedness with international clonal complexes encoding transferable multidrug resistance Clinical Microbiology and Infection ·Ørjan Samuelsen, Mark A. Toleman, V Hasseltvedt, Kurt Fuursted, Truls Michael Leegaard, Timothy R. Walsh, Arnfinn Sundsfjord, Christian G. Giske	2011	62
12	Combinatorial events of insertion sequences and ICE in Gram-negative bacteria FEMS Microbiology Reviews ·Mark A. Toleman, Timothy R. Walsh	2011	138
13	Does broad-spectrum -lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? Journal of Antimicrobial Chemotherapy ·Patrice Nordmann, Laurent Poirel, Mark A. Toleman, Timothy R. Walsh	2011	227
14	The emergence of pan-resistant Gram-negative pathogens merits a rapid global political response Journal of Antimicrobial Chemotherapy ·Timothy R. Walsh, Mark A. Toleman	2011	109
15	Characterization of a New Metallo-β-Lactamase Gene, bla _NDM-1 , and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from India Antimicrobial Agents and Chemotherapy ·Dongeun Yong, Mark A. Toleman, Christian G. Giske, R. Liss, Kurt Caswell, Kyungwon Lee, Timothy R. Walsh Hit paper breakdown →	2009	1860
16	Common regions e.g. orf513 and antibiotic resistance: IS91-like elements evolving complex class 1 integrons Journal of Antimicrobial Chemotherapy ·Mark A. Toleman	2006	100
17	Prevalence and antimicrobial susceptibility patterns among gastroenteritis-causing pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream infections in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (2003) International Journal of Antimicrobial Agents ·Jennifer M Streit, Ronald N. Jones, Mark A. Toleman, L. Stratchounski, Thomas R. Fritsche	2006	34
18	Evolution and dissemination of extended-spectrum β-lactamase-producing Klebsiella pneumoniae: Epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997–2003) Diagnostic Microbiology and Infectious Disease ·Joseph R. DiPersio, Lalitagauri M. Deshpande, Douglas J. Biedenbach, Mark A. Toleman, Timothy R. Walsh, Ronald N. Jones	2005	33
19	Evaluation of the contemporary occurrence rates of metallo-β-lactamases in multidrug-resistant Gram-negative bacilli in Japan: Report from the SENTRY Antimicrobial Surveillance Program (1998–2002) Diagnostic Microbiology and Infectious Disease ·Ronald N. Jones, Lalitagauri M. Deshpande, Jan Bell, John Turnidge, Shigeru Kohno, Yoichi Hirakata, Yasuo Ono, Yukihisa Miyazawa, Karl Heinz Kramer, Matsuhisa Inoue, 坦彦遠山, Mark A. Toleman	2004	26
20	Genetic characterization of a novel metallo- -lactamase gene, blaIMP-13, harboured by a novel Tn5051-type transposon disseminating carbapenemase genes in Europe: report from the SENTRY worldwide antimicrobial surveillance programme Journal of Antimicrobial Chemotherapy ·Mark A. Toleman	2003	71

About Mark A. Toleman

Mark A. Toleman is a scholar working on Molecular Medicine, Endocrinology, Applied Microbiology and Biotechnology, Pollution and Clinical Biochemistry, having authored 90 papers that have together received 9.7k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (74 papers), Bacterial biofilms and quorum sensing (28 papers), Vibrio bacteria research studies (16 papers), Pharmaceutical and Antibiotic Environmental Impacts (13 papers), Enterobacteriaceae and Cronobacter Research (11 papers), Infections and bacterial resistance (10 papers), Tuberculosis Research and Epidemiology (9 papers) and Antibiotic Use and Resistance (9 papers). The work is most often cited by research in Molecular Medicine (8.1k citations), Endocrinology (3.5k citations), Applied Microbiology and Biotechnology (1.3k citations), Pollution (2.6k citations) and Clinical Biochemistry (823 citations). Mark A. Toleman has collaborated with scholars based in United Kingdom, United States and Brazil. Frequent co-authors include Timothy R. Walsh, Patrice Nordmann, Laurent Poirel, Christian G. Giske, Dongeun Yong, Kyungwon Lee, David M. Livermore, Janis Weeks, Ronald N. Jones and Peter M. Bennett. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Journal of Antimicrobial Chemotherapy, International Journal of Antimicrobial Agents, Diagnostic Microbiology and Infectious Disease and The Lancet Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact